Anti-CanAg antibody conjugate

CN119136841APending Publication Date: 2024-12-13IKSUDA THERAPEUTICS LTD
View PDF -1 Cites 0 Cited by

Patent Information

Application Number
CN202380037771.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-04
Filing Date
2023-03-06
Publication Date
2024-12-13

AI Technical Summary

Technical Problem

Existing antibody-drug conjugates (ADCs) targeting CanAg antigens have problems with limited efficacy and high toxicity in the treatment of cancer, resulting in a small therapeutic index and difficulty in making further progress in clinical practice.

Method used

An antibody conjugate was developed with a humanized C242 antibody and a cytotoxic payload of pyrrolobenzodiazepine (PBD) to achieve stability between antibodies and drugs through specific linkers and chemical modification methods. Connect and effectively release drugs in tumor cells, reducing toxicity to normal cells.

Benefits of technology

The antibody conjugate showed improved safety and efficacy, had higher tumor selectivity, reduced toxicity to normal tissues, expanded the treatment window, and provided more effective anti-cancer efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005112517190000021
    Figure BDA0005112517190000021
  • Figure BDA0005112517190000022
    Figure BDA0005112517190000022
  • Figure BDA0005112517190000041
    Figure BDA0005112517190000041
Patent Text Reader

Abstract

The present invention relates to antibody conjugates targeting CanAg antigens, and compositions (e.g., pharmaceutical compositions) comprising the antibody conjugates. Also provided are methods of using the antibody conjugates and compositions, including methods for treating cancer.
Need to check novelty before this filing date? Find Prior Art